PDCD1 and hepatocellular carcinoma: In addition, immunotherapy has been proposed for HCC treatment, based on the finding that the programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) axis is an adaptive immune resistance mechanism used by cancer cells to overcome immune anti-tumor activity.